RecruitingNot ApplicableNCT06702293

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

Development and Testing of a Digital Psychological Tool to Improve Symptom Burden in Dermatology Patients


Sponsor

National University Hospital, Singapore

Enrollment

690 participants

Start Date

Feb 23, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.


Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Digital psychotherapeutic intervention and a behavioral approach called Healthy365 for people with eczema, psoriasis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALDigital psychotherapeutic intervention

Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.

BEHAVIORALHealthy365

Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.


Locations(1)

National University Hospital

Singapore, Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06702293


Related Trials